Limited access to GLP-1s in low-income and high-obesity regions threatens to widen existing health inequities, particularly in rates of diabetes, cardiovascular disease, and mobility-related conditions
Non-invasive markers and imaging often guide diagnosis and monitoring
Individuals who are overweight or have a Body Mass Index (BMI) of 30 or higher, indicating obesity People with health issues such as diabetes, high blood pressure, or high cholesterol Those who are in the process of weight loss and require additional support Individuals seeking to reduce unhealthy snacking habits People who have not seen results from other weight-loss methods, such as non-standard weight loss medications Anyone looking for a safe weight-loss solution with no side effects or risk of yo-yo weight gain Who Should Not Use the GLP-1
Temporary ALT/AST elevations occurred in a minority of participants and were generally tied to dose increases
References Abdrabou Abouelmagd, A., Abdelrehim, A
The new pill form changes how GLP-1s are taken but not the underlying reality that outcomes hinge on day-to-day behavior change
